Breast cancer treatment often causes menopause abruptly, or intensifies it — and then removes the treatment most women are offered for it. Being told "no hormones" and nothing else is a common experience, and it is not adequate care. There are real options. Here is what they are, so you can have a specific conversation with your oncology team rather than a closed one.

Where we stand: Menova is an independent publication. We sell no hormones and no supplements, we are not your doctor, and this is general education, not medical advice. Every decision here belongs with your oncology team, because it depends on your tumour type, your treatment, and your individual risk — more so than anything else we write about.

Why symptoms are often more severe

Three things make this different from natural menopause:

  • It can be abrupt. Chemotherapy, ovarian suppression, or removal of the ovaries can move you from premenopausal to postmenopausal in weeks rather than years. There is no gradual adjustment.
  • Endocrine therapy deepens it. Aromatase inhibitors work by driving estrogen very low, and tamoxifen has its own vasomotor effects. These are typically taken for five to ten years.
  • It often happens younger, which means a longer span of low estrogen and more to think about for bone and cardiovascular health.

The result is that women in this situation frequently have worse hot flashes, worse vaginal symptoms, and worse joint pain than women going through natural menopause — while having fewer treatment options offered.

Why this matters beyond comfort

There is a practical reason to treat symptoms rather than endure them: a significant proportion of women stop endocrine therapy early because of side effects, and completing it matters for outcomes. Treating the symptoms is part of making the cancer treatment work, not a luxury on top of it.

That framing is worth using in the conversation. "I'm struggling to stay on this" gets a different response from "I'm uncomfortable."

Non-hormonal options for hot flashes

Several have genuine evidence and are used specifically in this population:

  • Certain antidepressants at low doses reduce hot flashes. An important detail: some SSRIs — particularly paroxetine and fluoxetine — inhibit the enzyme that activates tamoxifen, so if you take tamoxifen, the choice of antidepressant matters. Venlafaxine is often preferred in that situation. Raise this explicitly; it is a genuine interaction and not always caught.
  • Gabapentin, which some women find particularly useful when night sweats dominate.
  • Clonidine and oxybutynin, both used with modest evidence.
  • Newer non-hormonal drugs targeting the brain pathway involved in hot flashes represent a real advance for women who cannot take estrogen; see non-hormonal prescription options for hot flashes.
  • CBT and clinical hypnosis, both of which have evidence for reducing how much hot flashes interfere with life.
  • Acupuncture, where the evidence is mixed but the risk is low.

Our wider guide is at non-hormonal menopause options, and the practical measures in night sweats apply here too.

Vaginal and urinary symptoms

This is where the impact is largest and the silence is deepest. Aromatase inhibitors commonly cause severe vaginal dryness, pain with sex, and urinary symptoms — and unlike hot flashes, these worsen over time rather than settling.

Start with non-hormonal measures, which help many women: vaginal moisturizers used on a regular schedule (different from lubricants), and lubricants for comfort during sex. Pelvic floor physiotherapy is genuinely useful and under-referred; see pelvic floor and bladder changes.

Low-dose vaginal estrogen is the harder conversation. It acts locally with minimal systemic absorption, and for women with significant symptoms not responding to non-hormonal measures it is discussed as an option — with more caution for women on aromatase inhibitors, since those drugs depend on estrogen being very low. Some guidance supports its use in selected women after shared decision-making with oncology.

The honest position: this is a genuine risk-benefit conversation, not a settled answer. What it should not be is an automatic refusal that leaves you with debilitating symptoms and no alternative offered. See is vaginal estrogen safe and GSM and urinary changes.

Non-estrogen prescription options exist and are worth asking about specifically.

Joint pain on aromatase inhibitors

Very common, and one of the main reasons women stop treatment. What helps: exercise — the evidence here is better than for most interventions and includes both aerobic and resistance work; switching to a different aromatase inhibitor, since response varies; duloxetine in some cases; and acupuncture, which has some supporting evidence in this specific setting. Do not simply endure it — say it is the reason you are considering stopping. See menopause joint pain.

Bone health becomes a priority

Aromatase inhibitors accelerate bone loss, and early menopause means more years without estrogen's protection. This needs active management rather than watching:

  • A baseline bone density scan and periodic monitoring
  • Adequate calcium and vitamin D
  • Resistance and impact exercise, the only intervention that builds bone
  • Bone-protective medications where indicated — these are commonly used alongside aromatase inhibitors, and if bone medication is prescribed, tell your dentist before any extraction or implant

See bone health in menopause.

What else deserves attention

  • Sleep, which is often wrecked by night sweats and worth treating directly; see what helps menopause insomnia
  • Mood. Rates of anxiety and depression are higher in this group, and this deserves treatment in its own right rather than being folded into "understandable"
  • Cognitive change, which is real and commonly reported after chemotherapy
  • Cardiovascular and metabolic health, given early estrogen loss; see heart health in menopause
  • Fertility, if relevant, which needs to be raised before treatment where possible

Things to be careful about

Two cautions specific to this situation:

  • Herbal and "natural" products marketed for menopause are not automatically safe here. Some have estrogenic activity or interact with endocrine therapy. Check anything you take with your oncology team or pharmacist — including supplements you consider harmless.
  • Compounded "bioidentical" hormone products marketed as safe after breast cancer are not supported by evidence, and the claim is a marketing one; see compounded versus FDA-approved.

How to raise it

Be specific, and make the stakes explicit:

"The hot flashes and vaginal dryness on this aromatase inhibitor are severe enough that I'm struggling to keep taking it. I know systemic hormones aren't an option. What non-hormonal treatments would you consider, and could I be referred to someone who specialises in managing menopause after breast cancer?"

Ask about a referral. Menopause-after-cancer clinics and specialist nurses exist in many centres, and this is exactly what they are for. Our guides to not being dismissed and what to bring to an appointment apply here, and the free printable visit prep sheet gives you a page to hand over.

The free 30-day symptom tracker is particularly useful in this setting, because "hot flashes 14 times a day, waking 4 times a night" makes the case that "I'm struggling" does not.

The point

Being told no hormones is a legitimate clinical decision. Being told nothing else is not. There is a real toolkit here, and asking for it by name is usually what gets it offered.

This article is general education, not medical advice, and not a recommendation of any treatment after breast cancer. Every option here depends on your tumour type, treatment, and individual risk — decide with your oncology team, and report any new breast changes or symptoms promptly.

Sources: The Menopause Society, ACOG — Clinical Guidance, National Cancer Institute — Treatment Side Effects, and NICE NG101 — Early and Locally Advanced Breast Cancer.